Print ISSN: 2393-9079
Online ISSN: 2393-9087
CODEN : IJPPTK
Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award programs. With more...Review Article
Author Details :
Volume : 9, Issue : 1, Year : 2022
Article Page : 24-28
https://doi.org/10.18231/j.ijpp.2022.005
Abstract
This narrative review focussed on Diabetes which has emerged as a significant public health problem after cardiovascular diseases and the sixth leading cause of mortality worldwide. India faces a massive burden of
Diabetes, which parallels a similar rise in obesity and metabolic syndrome. (Diabetes mellitus currently had
a global prevalence of 6.4%, aged 20-79 years in 2010). Diabetes prevalence among adults over 18 years has increased from 4.7% in 1980 to 8.5 % in 2014 (WHO) and is estimated to be 10.2% by 2030 (IDF). India has the second-largest number of diabetics (about a 61million, i.e., the prevalence of 8.8% and about 77 million, i.e., majority of 8.9%). The number is likely to increase to 101 million (prevalence of 9.9%) by 2030. These rising figures are primarily due to marked transitions leading to unhealthy diets and physical inactivity. That causes problems like retinopathy, cardiomyopathy, nephropathy, and neurodegenerative diseases. Diabetes is the most common progressive heterogeneous endocrine disorder with devastating multi-systemic complications characterized by altered glucose homeostasis and insulin resistance. Diabetes is principally divided into two types Diabetes Insipidus and Diabetes Mellitus (DM). Again, DM is of 2
types — Type 1(Juvenile/Insulin-dependent) and Type-2 (Insulin resistance). Type1-DM is prevalent in the young population, associated with a lack of insulin production due to auto-immune destruction of beta cells of the pancreas. In contrast, Type2-DM is due to the inability of cells/tissues to respond to insulin appropriately. Long-term chronic hyperglycemia leads to organ dysfunction leads to organ failure, especially kidney, eyes, heart, and blood vessels.
Keywords: T2DM, Antidiabetics, Newer drugs, Therapeutics
How to cite : Chakraverty R, Kumar N, Chavan R, Thorat V H, Patil A, Jadhav S, Emerging treatment modalities for the management of diabetes mellitus: A review. Indian J Pharm Pharmacol 2022;9(1):24-28
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.